Holen Sie sich die Stockscreener-App
6.91
4.69%
-0.34
Handel nachbörslich:
7.04
0.13
+1.88%
Schlusskurs vom Vortag:
$7.25
Offen:
$7.15
24-Stunden-Volumen:
38,873
Relative Volume:
0.57
Marktkapitalisierung:
$77.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.73%
1M Leistung:
-13.62%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.90
$7.15
1-Wochen-Bereich:
$6.90
$7.69
52-Wochen-Spanne:
$6.90
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Firmenname
Imagenebio Inc
Sektor
Branche
Telefon
857-343-8292
Adresse
12526 HIGH BLUFF DRIVE, SAN DIEGO
Vergleichen Sie IMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
6.91 | 81.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Eingeleitet | Leerink Partners | Outperform |
Imagenebio Inc Aktie (IMA) Neueste Nachrichten
Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks
Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa
ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus
ImageneBio assumed at Underperform from Neutral at Wedbush - TipRanks
Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India
Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - MarketScreener
ImageneBio Highlights IMG-007 in Corporate Update - TipRanks
ImageneBio, Inc Updates Corporate Presentation for Q4 2025 - TradingView
FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World
William Blair Estimates ImageneBio FY2025 Earnings - Defense World
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Yahoo Finance
ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World
ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - TipRanks
[424B3] ImageneBio, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results - TradingView
ImageneBio, Inc. SEC 10-Q Report - TradingView
ImageneBio Reports Third Quarter 2025 Financial Results and - GlobeNewswire
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - Yahoo Finance
ImageneBio Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - The Manila Times
ImageneBio Expands Board, Appoints New Audit Chair - TipRanks
ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025 - MarketScreener
ImageneBio initiated with an Outperform at Leerink - MSN
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update - Defense World
Miragene Inc. Announces Extension of Key Service Agreement - MarketScreener
Imagenebio Inc elects not to renew agreement with MirageneSEC filing - MarketScreener
ImageneBio IncOn Oct 23, Elects Not To Renew Agreement With MirageneSEC Filing - TradingView
ImageneBio Extends Agreement with Miragene Inc. - TipRanks
Imagenebio IncExtends Term for Miragene Se - 富途牛牛
Leerink Partners initiates Imagene Bio stock with Outperform rating By Investing.com - Investing.com South Africa
Leerink Partners initiates Imagene Bio stock with Outperform rating - Investing.com India
IMA Analyst Forecasts - Quiver Quantitative
Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target - MarketScreener
This Albemarle Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Leerink Partners Initiates Coverage on ImageneBio (IMA) with Out - GuruFocus
ImageneBio’s IMG-007: A Promising Blockbuster in Atopic Dermatitis with Strategic Leadership and Competitive Edge - TipRanks
Weiss Ratings Initiates Coverage on ImageneBio (NASDAQ:IMA) - Defense World
ImageneBio, Inc.Common Stock (Nasdaq:IMA) Stock Quote - FinancialContent
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer By Investing.com - Investing.com Nigeria
ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025 - MarketScreener
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer - Investing.com
ImageneBio Appoints New Interim Financial Officer - TipRanks
OX40 Targeted Therapy Clinical Trials Anti OX40 Antibody Development Market Opportunity Insight 2026 - GlobeNewswire Inc.
ImageneBio CFO Jotin Marango resigns, company to begin search for successor - Investing.com Australia
ImageneBio Charts New Course Following Merger Completion - Ad-hoc-news.de
ImageneBio CFO Resignation Announced - TipRanks
ImageneBio (NASDAQ:IMA) Cut to “Hold” at Zacks Research - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to Hold - Defense World
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - msn.com
ImageneBio (NASDAQ:IMA) Stock Price Down 1.2% – Here’s Why - Defense World
ImageneBio files to sell 2.51M shares of common stock for holders - MSN
Finanzdaten der Imagenebio Inc-Aktie (IMA)
Es liegen keine Finanzdaten für Imagenebio Inc (IMA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):